MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
convertible notes payable -...
$1,640,000
Proceeds from issuance of
convertible notes payable
$870,000
Proceeds from issuance of
common stock of...
$850,000
Net cash provided by
financing activities
$3,087,006
Effect of exchange
rates on cash and...
$550
Canceled cashflow
$272,994
Net decrease in cash
and restricted cash
-$238,435
Canceled cashflow
$3,087,556
Stock-based compensation
$1,237,546
Other accrued
expenses
$986,003
Prepaid expenses and
other current assets
-$478,387
Accrued interest
$201,772
Non-cash operating lease
expense
$48,128
Depreciation
$1,863
Repayment of short-term
note payable
$272,994
Net cash used in
operating activities
-$3,325,991
Canceled cashflow
$2,953,699
Net loss
-$5,505,124
Accounts payable
-$390,331
Unearned grant revenue
-$336,108
Operating lease liability
-$48,127
Back
Back
Cash Flow
source: myfinsight.com
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)